Abstract:
Chemotherapy induced neutropenia, febrile neutropenia, thrombocytopenia and anemia were the common toxicities among breast cancer patients treated with doxorubicincyclophosphamide followed by paclitaxel regimen. Those toxicities may lead to chemotherapy dose adjustment, delay and discontinuation that may compromise therapeutic outcomes.